This page shows the latest Evotec news and features for those working in and with pharma, biotech and healthcare.
It remains firmly committed to women’s health however, and just last week added to its pipeline in this area by signing a five-year research alliance with Evotec focusing on ... The Evotec and Daré deals sandwiched two other agreements signed in the
There has been little progress in how these and other related conditions are diagnosed and treated, according to Evotec. ... Bayer and Evotec will both contribute drug targets to the alliance as well as other technology platforms, and will jointly
in nephrology clinical development and commercialisation,” said Cord Dohrmann, chief scientific officer at Evotec. ... The discovery of novel nephrology therapeutics will be aided by analysis of clinical data provided by Evotec from the UK kidney
Will challenge AstraZeneca and others in DNA damage response. German biotech Evotec has decided to bundle its cancer therapeutic programmes focused on DNA damage response (DDR) into a new spin-off ... virtual” spin out that will still have access to
This deal extends Exscientia’s list of partnerships with pharma and biotech companies, with existing collaborations involving Roche, GSK, Sanofi and Evotec.
Galapagos will have access to specific screening formats at Evotec to support the final pre-clinical development. ... We highly regard the scientific know-how of Evotec, and are hence very much looking forward to collaborating with the team.".
More from news
Approximately 16 fully matching, plus 24 partially matching documents found.
We’ve also signed numerous major pharma collaborations with companies including Roche, Celgene, Sanofi, GSK and Evotec, estimated to be worth over $1bn in milestones and royalties.
Last month, Johnson &Johnson Innovation, Takeda and Evotec became the latest pharma research groups to join the initiative, alongside existing strategic partners AbbVie, Astex Pharmaceuticals, Eisai, Lilly and MSD. ... We’re excited to welcome Johnson
For example, Evotec, the German small molecule development company, is acquiring for $300m the US preclinical development company, Aptuit. ... 400. Aptuit (US). Evotec (DE). Company acquisition. Drug discovery and development to IND submission including
320. Evotec (Germany). Celgene (US). Discovery collaboration. Induced pluripotent stem cells for neurodegenerative diseases. ... upfront. And although the upfronts are a modest percentage of the headline figure, ranging from < 1% (BioInvent) to 15%
Acquisition of Priority Review Voucher. 350. Evotec. Sanofi. Beta cell modulating treatments for diabetes. ... Acquisition ‐ company. 300. Aperion Biologics Evotec. Sanofi. To develops mall molecule immuno‐therapies.
More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.
He has also served on several boards including Ablynx, Evotec and Acambis.
Cites health reasons. Evotec's CEO Dr Werner Lanthaler, has temporarily stood down from his role within the company due to health reasons.
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....